These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15320809)

  • 1. Recent developments in cardiovascular drug therapy: treatment of atrial arrhythmias with new class III drugs and beyond.
    Pürerfellner H
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Jan; 2(1):79-91. PubMed ID: 15320809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
    Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What niche will newer class III antiarrhythmic drugs occupy?
    Singh BN; Sarma JS
    Curr Cardiol Rep; 2001 Jul; 3(4):314-23. PubMed ID: 11406090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.
    Blaauw Y; Schotten U; van Hunnik A; Neuberger HR; Allessie MA
    Cardiovasc Res; 2007 Jul; 75(1):89-98. PubMed ID: 17466958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug choices in the treatment of atrial fibrillation.
    Reiffel JA
    Am J Cardiol; 2000 May; 85(10A):12D-19D. PubMed ID: 10822036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
    Knobloch K; Brendel J; Rosenstein B; Bleich M; Busch AE; Wirth KJ
    Med Sci Monit; 2004 Jul; 10(7):BR221-8. PubMed ID: 15232496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid therapy of atrial fibrillation.
    Santini M; Pignalberi C; Ricci R; Calò L
    Ital Heart J; 2002 Oct; 3(10):571-8. PubMed ID: 12478814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.
    Nattel S; Khairy P; Roy D; Thibault B; Guerra P; Talajic M; Dubuc M
    Drugs; 2002; 62(16):2377-97. PubMed ID: 12396229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.